# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Duke Kahanamoku (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML050-SYN
- Date: 2026-03-30
- Fictional facility: St. Posthumous Health Center
- Fictional author: Kawika Lindgren-Morrison, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Two-week review: echocardiogram, heart failure consultation and the diagnosis. **S**

## History of present illness

Mr. Kahanamoku returns two weeks after intake and is seen the same day by Dr. Abernathy-Chen of heart failure cardiology after his echocardiogram this morning. At his wish, two members of his ʻohana joined the discussion with the cardiologist. On furosemide 40 mg he has lost 2.6 kg; his ankles swell less, and he now sleeps on one pillow. He is still breathless walking up a slope and has not been back in the water. He has had no chest pain, palpitations, fainting or lightheadedness. He took his last lisinopril dose this morning. The echocardiogram shows a weak heart muscle with an ejection fraction of 30% and an old scar at the front and tip of the heart. **S**

| Element | Detail |
|---|---|
| Since intake | Weight down 2.6 kg; less ankle swelling; one pillow |
| Function | Breathless walking uphill; NYHA class III |
| Echocardiogram | Ejection fraction 30%; thinned, akinetic anterior wall and apex; moderate functional mitral regurgitation |
| Last lisinopril dose | This morning |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Cardiovascular | Positive | Breathless walking uphill; less ankle swelling; no chest pain, palpitations or fainting |
| Respiratory | Negative | No cough; orthopnea resolved |
| Genitourinary | Negative | Passing more urine in the mornings |
| Musculoskeletal | Negative | No cramps |

4 systems reviewed. **S**

## Current medications

- Aspirin 81 mg delayed-release oral tablet, one tablet daily **S**
- Atorvastatin 80 mg oral tablet, one tablet daily **S**
- Furosemide 40 mg oral tablet, one tablet every morning **S**
- Sacubitril 24 mg / valsartan 26 mg oral tablet, one tablet twice daily, first dose 36 hours after the last lisinopril **S**
- Carvedilol 3.125 mg oral tablet, one tablet twice daily with food, starting the evening after the last metoprolol tartrate **S**
- Empagliflozin 10 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating or drinking **S**
- Ferric carboxymaltose 750 mg (15 mL vial, 50 mg/mL) by intravenous infusion, two doses two weeks apart **S**

## Allergies

- No known allergy **S**

## Objective

BP 134/82 mmHg; pulse 86 bpm; respirations 18/min; temperature 36.6 °C; oxygen saturation 96% on room air; weight 95 kg; BMI 27.8 kg/m². All vital signs are synthetic.

Sodium: 137 mmol/L; Potassium: 3.9 mmol/L; Creatinine: 1.08 mg/dL; eGFR (CKD-EPI 2021): 76 mL/min/1.73 m²; Glucose: 98 mg/dL; Magnesium: 1.9 mg/dL; LVEF by echocardiogram: 30% (low). All results are synthetic.

## Change since baseline

- Sodium: 138 mmol/L at baseline, 137 mmol/L at this visit **S**
- Potassium: 4.2 mmol/L at baseline, 3.9 mmol/L at this visit **S**
- Creatinine: 1.02 mg/dL at baseline, 1.08 mg/dL at this visit **S**
- eGFR (CKD-EPI 2021): 81 mL/min/1.73 m² at baseline, 76 mL/min/1.73 m² at this visit **S**
- Glucose: 102 mg/dL (high) at baseline, 98 mg/dL at this visit **S**
- Magnesium: 2 mg/dL at baseline, 1.9 mg/dL at this visit **S**

## Immunizations given today

- Pneumococcal conjugate vaccine PCV20 **S**

## Physical examination

| System | Finding |
|---|---|
| General | Comfortable at rest; blood pressure 134/82, pulse 86; weight 95.0 kg, down 2.6 kg |
| Neck | Jugular venous pressure 3 cm above the sternal angle, down from 6 |
| Cardiovascular | Regular rhythm; displaced apex; soft S3; apical systolic murmur |
| Respiratory | Fine crackles at both bases only |
| Extremities | Trace ankle edema, from 2+ |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Heart failure with reduced ejection fraction from ischemic cardiomyopathy, NYHA class III** (I50.22). Breathlessness, ankle swelling, NT-proBNP 2,450 pg/mL and an ejection fraction of 30% with a thinned, akinetic anterior wall and apex establish HFrEF from an old anterior infarction. Less congested on furosemide. Potassium 3.9 mmol/L and creatinine 1.08 mg/dL (eGFR 76) two weeks after furosemide. Dr. Abernathy-Chen agrees and advises starting all four medicine classes within weeks. **S**
   - Stop lisinopril (last dose this morning); start sacubitril-valsartan 24/26 mg twice daily 36 hours after that dose.
   - Stop metoprolol tartrate; start carvedilol 3.125 mg twice daily with food this evening.
   - Start empagliflozin 10 mg daily, with sick-day rules.
   - Continue furosemide 40 mg daily and daily weights.
   - Spironolactone at the next visit if potassium and kidney function allow.
   - Metabolic panel in two weeks.
2. **Iron deficiency without anemia** (E61.1). Ferritin 62 ng/mL and transferrin saturation 16% in HFrEF: intravenous iron improves symptoms and exercise capacity. **S**
   - Ferric carboxymaltose 750 mg intravenously today, and again in two weeks.
3. **Coronary artery disease with an old anterior infarction** (I25.2). No angina. A new reduction in heart function needs an ischemic evaluation. **S**
   - Coronary angiography next week.
   - Continue aspirin 81 mg and atorvastatin 80 mg.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure and heart rate (seated and standing) | Every visit | Completed today | 134/82 mmHg, pulse 86 |
| Examination | Weight, volume status (jugular venous pressure, edema, lungs) and NYHA class | Every visit | Completed today | 95.0 kg (down 2.6); jugular venous pressure 3 cm; basal crackles; trace edema; NYHA III |
| Laboratory | Metabolic panel (sodium, potassium, creatinine and eGFR) and magnesium | One to two weeks after starting or changing a diuretic, ARNI, MRA or SGLT2 inhibitor; then every three to six months | Completed today | Two weeks after furosemide: sodium 137, potassium 3.9, creatinine 1.08 mg/dL (eGFR 76), magnesium 1.9 |
| Imaging | Echocardiogram | At diagnosis; repeat after three to six months of optimized therapy for device decisions, or with unexplained change | Completed today | Ejection fraction 30%; thinned, akinetic anterior wall and apex; left ventricular end-diastolic diameter 62 mm; moderate functional mitral regurgitation |
| Examination | ECG (rhythm and QRS width) | At diagnosis and with change or device consideration | Up to date | At intake: sinus rhythm, old anterior Q waves, QRS 104 ms |
| Laboratory | NT-proBNP | At diagnosis; selectively for prognosis (not for titration) | Up to date | 2,450 pg/mL at intake |
| Laboratory | Initial workup (blood count, TSH, hemoglobin A1c, lipids, liver tests) | At diagnosis | Up to date | Hemoglobin 13.4, TSH 2.1, hemoglobin A1c 5.9%, LDL 92, ALT 28 at intake |
| Medication safety | Iron studies (ferritin, transferrin saturation) and intravenous iron | At diagnosis; after repletion and about yearly | Completed today | Ferritin 62 and transferrin saturation 16% at intake; ferric carboxymaltose 750 mg given today, second dose in two weeks |
| Medication safety | Guideline-directed medical therapy: ARNI, evidence-based beta-blocker, MRA and SGLT2 inhibitor, toward target doses | Every two weeks during titration | Completed today | Sacubitril-valsartan from 36 hours after the last lisinopril; carvedilol in place of metoprolol tartrate; empagliflozin; spironolactone next |
| Survey | KCCQ-12 heart failure health status | At diagnosis, then every three to six months | Up to date | 38 at intake; next in two weeks |
| Examination | Primary-prevention ICD evaluation (and CRT if QRS is wide) | After at least 90 days of optimized therapy, and at least 40 days after a myocardial infarction | Due | Not before 90 days of optimized therapy; QRS 104 ms, so no CRT |
| Laboratory | Lipid panel | Four to twelve weeks after a statin change, then every three to twelve months | Ordered | LDL 92 mg/dL at intake; atorvastatin raised to 80 mg; panel due four to twelve weeks after the change |
| Survey | Depression screen (PHQ-2, then PHQ-9 if positive) | Periodically | Up to date | PHQ-2 1 at intake |
| Referral | Cardiac rehabilitation for heart failure | When eligible: ejection fraction 35% or below, NYHA II to IV, six weeks of stable therapy and no procedure in six weeks | Due | Not yet eligible: needs six weeks of stable therapy and six weeks after angiography |
| Self-management | Self-care: daily weights, sodium, sick-day rules and symptoms to report | Every visit | Completed today | Daily weights with a written plan; sodium plan; sick-day rules for empagliflozin |
| Examination | Vaccinations (pneumococcal, influenza, COVID-19, RSV) | Pneumococcal once; others yearly or per schedule | Completed today | PCV20 today; influenza, COVID-19 and RSV in the autumn |
| Self-management | Culturally safe care: ʻohana involvement as he chooses; his own healing practices | Every visit | Completed today | ʻOhana present at his wish; decisions his; lomilomi through Ke Ola Mamo offered |
| Referral | Heart failure cardiology consultation | At diagnosis | Completed today | Seen by Dr. Abernathy-Chen today |

## Goal progress

- Euvolemia: no ankle swelling or orthopnea, with a steady dry weight. In progress; target 2026-04-27. **S**
- All four guideline-directed medicines at the highest doses he tolerates within three months. In progress; target 2026-09-28. **S**
- KCCQ-12 at least 20 points higher and NYHA class I to II within six months. In progress; target 2026-09-28. **S**
- Back in the ocean safely, swimming in calm water with a companion. In progress; target 2026-09-28. **S**
- LDL cholesterol below 70 mg/dL. In progress; target 2026-04-27. **S**

## Medication changes

- Stopped: Metoprolol tartrate 25 mg oral tablet, one tablet twice daily **S**
- Stopped: Lisinopril 10 mg oral tablet, one tablet daily **S**
- Started: Sacubitril 24 mg / valsartan 26 mg oral tablet, one tablet twice daily, first dose 36 hours after the last lisinopril **S**
- Started: Carvedilol 3.125 mg oral tablet, one tablet twice daily with food, starting the evening after the last metoprolol tartrate **S**
- Started: Empagliflozin 10 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating or drinking **S**
- Started: Ferric carboxymaltose 750 mg (15 mL vial, 50 mg/mL) by intravenous infusion, two doses two weeks apart **S**

## Guideline basis

- 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022), American Heart Association, American College of Cardiology, and Heart Failure Society of America (Circulation 2022;145(18):e895-e1032)
- 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction (2024), American College of Cardiology (J Am Coll Cardiol 2024;83(15):1444-1488)
- 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023), American Heart Association and American College of Cardiology (Circulation 2023;148(9):e9-e119)
- CMID: Clinical Monitoring Intelligence Database, heart failure and ischemic heart disease monographs (2026), Aether Forge
- Ke Ola Mamo: a Native Hawaiian Health Care System serving Oʻahu (medical care, lomilomi and community health workers) (2026), Ke Ola Mamo

## Follow-up

- Coronary angiography next week. Review in two weeks with a metabolic panel, the KCCQ-12 and the second iron infusion. Call for a weight gain of more than 1 kg in a day or 2 kg in a week, lightheadedness, or breathlessness at rest; call 911 for chest pain or fainting. **S**
- Next scheduled visit 2026-04-13: two-week review after sacubitril-valsartan, carvedilol and empagliflozin: kidney function, potassium, angiography result and the next medicine. **S**
